U.S. Congressional Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not
This article was originally published in PharmAsia News
Executive Summary
A U.S. House of Representatives Energy and Commerce Committee investigation into who caused contamination of heparin supplies in 2007 and 2008, how it was done, and U.S. FDA's handling of the crisis, could revive interest in legislation designed to strengthen FDA's oversight of drugs and other medical products entering the U.S. from overseas
You may also be interested in...
U.S. Legislative Response to Heparin Crisis Begins to Take Shape
The broad outlines of the timing and scope of a U.S. legislative response to the global pharmaceutical supply chain crisis are taking shape
U.S. Legislative Response to Heparin Crisis Begins to Take Shape
The broad outlines of the timing and scope of a U.S. legislative response to the global pharmaceutical supply chain crisis are taking shape
U.S. FDA Foreign Inspections User Fee Program Getting Push From Congress
The pharmaceutical industry is facing an increasingly aggressive push to create user fees for manufacturing inspections